title: Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major.
abstract: In order to evaluate the immunogenicity, safety, and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major, 31 subjects (19 males; mean age 17.8±8.7 years) with β-thalassemia major and 28 age- and gender-matched healthy controls were enrolled. Four weeks after vaccination, seroconversion rates were about 80% and seroprotection rates 100% in both groups. Three months after vaccination, most of the subjects remained seroconverted and the seroprotection rates were 93.5% among the patients and 100% among the controls. Safety and tolerability were also very good, with no differences between the groups.
authors.affiliation: Department of Maternal and Pediatric Sciences, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Commenda 9, 20122 Milano, Italy.
authors.forename: Susanna
authors.initials: S
authors.lastname: Esposito
authors.forename: Emanuela
authors.initials: E
authors.lastname: D'Angelo
authors.forename: Cristina
authors.initials: C
authors.lastname: Daleno
authors.forename: Francesco
authors.initials: F
authors.lastname: Peia
authors.forename: Alessia
authors.initials: A
authors.lastname: Scala
authors.forename: Domenico
authors.initials: D
authors.lastname: Serra
authors.forename: Nadia
authors.initials: N
authors.lastname: Mirra
authors.forename: Carlotta
authors.initials: C
authors.lastname: Galeone
authors.forename: Nicola
authors.initials: N
authors.lastname: Principi
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D000917:Antibody Formation; D002648:Child; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control*; D008297:Male; D011136:Polysorbates / Q000494:pharmacology*; D013185:Squalene / Q000494:pharmacology*; D055815:Young Adult; D017086:beta-Thalassemia / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007252:Influenza Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; D013185:Squalene